Skip to main content

Table 2 Univariate analysis of variables associated with ICU, hospital and 6-month mortality

From: Mortality of septic shock patients is associated with impaired mitochondrial oxidative coupling efficiency in lymphocytes: a prospective cohort study

Variables

ICU

P

Hospital

P

Six months

P

Survivors n = 43

Non-survivors n = 32

Survivors n = 32

Non-survivors n = 43

Survivors n = 25

Non-survivors n = 50

Age

64.14 (18.1)

67.16 (14.7)

0.443

61.97 (16.5)

68.00 (16.6)

0.122

62.1 (14.0)

67.1 (17.8)

0.228

Clinical admission at ICU

25 (58%)

21 (66%)

0.51

21 (66%)

25 (58%)

0.51

16 (64%)

30 (60%)

0.737

Sex (male)

26 (60%)

16 (50%)

0.366

18 (57%)

24 (56%)

0.97

15 (60%)

27 (54%)

0.622

Pulmonary sepsis

21 (51%)

12 (38%)

0.24

18 (56%)

16 (37%)

0.101

13 (52%)

21 (42%)

0.412

Solid neoplasia

13 (30%)

4 (11%)

0.07

9 (28%)

8 (18%)

0.33

6 (24%)

11 (22%)

0.845

Hematological neoplasia

2 (4.6%)

3 (9.4%)

0.417

1 (3.1%)

4 (9.3%)

0.386

0 (0%)

5 (10%)

0.162

Cirrhosis

1 (2.3%)

4 (13%)

0.081

1 (3.1%)

4 (9.3%)

0.386

1 (4.0%)

4 (8.0%)

0.66

COPD

7 (16%)

4 (13%)

0.647

5 (16%)

6 (14%)

0.84

3 (12.0%)

8 (16%)

0.742

CKD

5 (12%)

2 (6.2%)

0.428

5 (16%)

2 (4.6%)

0.11

4 (16%)

3 (6%)

0.161

Chronic hypertension

11 (26%)

13 (41%)

0.167

9 (28%)

15 (35%)

0.534

7 (28%)

17 (34%)

0.6

Diabetes

11 (26%)

10 (31%)

0.589

10 (32%)

11 (26%)

0.589

9 (36%)

12 (24%)

0.275

SvO2 (%)

68.01 (6.1)

71.36 (11.6)

0.215

67.71 (9.0)

70.70 (11.1)

0.266

68.18 (9.1)

70.06 (10.9)

0.504

Lactate D1 (mmol/L)

1.4 (1.1–2.1)

2.8 (2.0–4.0)

0.002

1.4 (1.1–1.9

2.55 (1.7–3.6

0.015

1.4 (0.9–1.6)

2.2 (1.6–3.5)

0.041

SOFA D1

7.63 (3.0)

1.0 (2.4)

< 0.0001

7.25 (2.55)

9.67 (2.95)

< 0.0001

7.40 (2.6)

9.26 (3.0)

0.011

SOFA D3

3 (2–5)

12.5 (7–19.5)

< 0.0001

3 (1.7–5)

9 (4–16.5)

< 0.0001

3 (1–4)

7.5 (3.25–15.5)

< 0.0001

ΔSOFA < 0

38 (88%)

11 (34%)

< 0.0001

28 (88%)

21 (49%)

< 0.0001

22 (88%)

27 (54%)

0.004

SAPS 3

73.98 (13.2)

78.60 (12.1)

0.1

72.16 (13.1)

78.77 (12.0)

0.026

70.68 (11.2)

78.58 (12.9)

0.011

CRP (mg/L)

153 (69.7–216)

220 (119–284)

0.02

153 (69–223)

196 (119–269)

0.062

153(72.6–209)

188 (98–258)

0.076

CRT D1 (s)

4 (2–4)

5.5 (3–8)

0.04

3.5 (2–4)

4 (3–7)

0.046

4 (3–4)

4 (2.25–7)

0.319

BCE D1

0.354 (0.1)

0.243 (0.1)

< 0.0001

0.378 (0.1)

0.254 (0.1)

< 0.0001

0.380 (0.1)

0.270 (0.1)

< 0.0001

BCE D3

0.456 (0.18)

0.210 (0.1)

< 0.0001

0.535 (0.1)

0.215 (0.1)

< 0.0001

0.543 (0.1)

0.267 (0.2)

< 0.0001

ΔBCE > 0

33 (77%)

2 (6.3%)

< 0.0001

31 (97%)

4 (9.3%)

< 0.0001

24 (96%)

11 (22%)

< 0.0001

  1. Δ indicates the pairwise variation between values obtained at day 3 and day 1, mathematically represented as day 3–day 1 for the indicated variable. Data are mean (SD), median (IQR), or n (%).CRP C-reactive protein, SOFA sequential organ failure assessment, ICU intensive care unit, SAPS 3 simplified acute physiology score 3, BCE biochemical coupling efficiency, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, CRT cardiac resynchronization therapy